Company news
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) news
Xenon Pharmaceuticals Inc. news releases on 6ix. Latest, Oct 2, 2026: Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Press releases & updates
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 2, 2026
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 1, 2026
Xenon to Present at TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
September 21, 2026
Xenon Announces Azetukalner NDA Submission to FDA for Focal Seizures and Provides Update on Psychiatry Clinical Program
September 17, 2026
Xenon to Present at Wells Fargo Healthcare Conference
September 3, 2026
Xenon to Highlight Phase 3 X-TOLE2 Clinical Data and Rational Polytherapy Potential for Azetukalner at EEC 2026
August 26, 2026
Xenon Reports Q2 2026 Financial Results and Provides Business Update
August 6, 2026
Xenon to Report Q2 2026 Financial Results on August 6, 2026
July 30, 2026
Xenon Reports Q1 2026 Financial Results and Provides Business Update
May 7, 2026
Xenon to Report Q1 2026 Financial Results on May 7, 2026
April 30, 2026
Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual Meeting
April 19, 2026
Xenon to Highlight Phase 3 X-TOLE2 & Long-Term Data for Azetukalner in Focal Onset Seizures at 2026 AAN Annual Meeting
April 6, 2026
Xenon Pharmaceuticals Announces Closing of $747.5 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
March 12, 2026
Xenon Pharmaceuticals Announces Pricing of Upsized $650.0 Million Public Offering
March 9, 2026
Xenon Announces Positive Topline Data from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures (FOS)
March 8, 2026
Xenon to Announce Topline Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures on Monday, March 9, 2026
March 7, 2026
Xenon Reports Q4 and Full Year 2025 Financial Results and Provides Business Update
February 25, 2026
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 16, 2026
Xenon Outlines Key Upcoming Milestones at the 2026 J.P. Morgan Healthcare Conference
January 12, 2026
Xenon to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 4, 2026
Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025
December 4, 2025
Xenon Announces Investor Webinar Highlighting Azetukalner and Epilepsy Data from AES 2025
December 2, 2025
Xenon to Present New Azetukalner OLE Study Data in Epilepsy at AES 2025
November 24, 2025
Xenon to Present at Upcoming Investor Conferences
November 5, 2025
Xenon Reports Third Quarter 2025 Financial Results & Business Update
November 2, 2025
Xenon to Report Q3 2025 Financial Results on November 3, 2025
October 26, 2025
Xenon Announces Appointment of Tucker Kelly as Chief Financial Officer
October 15, 2025
Xenon Announces Upcoming Investor Webinar to Discuss Early-Stage Ion Channel Programs for the Potential Treatment of Pain
September 24, 2025
Design Therapeutics Appoints Justin Gover to Board of Directors
September 10, 2025
Xenon Reports Second Quarter 2025 Financial Results & Business Update
August 10, 2025
Xenon to Report Q2 2025 Financial Results on August 11, 2025
August 3, 2025
Xenon Joins the Russell 3000® and Russell 2000® Indexes
June 26, 2025
Xenon Announces Appointment of Darren Cline as Chief Commercial Officer
June 23, 2025
Xenon to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
June 2, 2025
Xenon to Present at the 2025 RBC Capital Markets Global Healthcare Conference
May 13, 2025
Xenon Reports First Quarter 2025 Financial Results and Provides Business Update
May 11, 2025
Xenon to Report Q1 2025 Financial Results on May 12, 2025
May 4, 2025
Xenon to Showcase Long-Term 36-Month Azetukalner Data at AAN 2025
April 3, 2025
Xenon to Present at Stifel 2025 Virtual CNS Forum
March 11, 2025
Xenon Reports Fourth Quarter & Full Year 2024 Financial Results and Business Update
February 26, 2025
Xenon to Present at the 45th Annual TD Cowen Healthcare Conference
February 24, 2025
Xenon to Report Q4 and Full Year 2024 Financial Results on February 27, 2025
February 19, 2025
Xenon Outlines Key Corporate Milestone Opportunities for 2025
January 12, 2025
Xenon to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 6, 2025
Xenon Showcases New Long-Term Azetukalner Data from X-TOLE OLE Study in FOS at AES 2024
December 5, 2024
Xenon to Showcase New Long-Term Azetukalner Data at AES 2024
November 24, 2024
Xenon Reports Q3 2024 Financial Results and Business Update
November 11, 2024
Xenon to Report Q3 2024 Financial Results on November 12, 2024
November 4, 2024
Xenon to Present at BofA Securities 2024 CNS Therapeutics Virtual Conference
October 1, 2024
Xenon Showcases Azetukalner Data at 15th European Epilepsy Congress
September 8, 2024